Switch theme
Sign up to access all valuation multiples
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
2019
51
Last FY Revenue n/a
LTM EBITDA -$194M
$672M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Mineralys Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$194M.
In the most recent fiscal year, Mineralys Therapeutics achieved revenue of n/a and an EBITDA of -$192M.
Mineralys Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Mineralys Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$194M | XXX | -$192M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$197M | XXX | -$192M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$186M | XXX | -$178M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Mineralys Therapeutics's stock price is $16.
Mineralys Therapeutics has current market cap of $1.0B, and EV of $672M.
See Mineralys Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $672M | $1.0B | XXX | XXX | XXX | XXX | $-3.50 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Mineralys Therapeutics has market cap of $1.0B and EV of $672M.
Mineralys Therapeutics's trades at n/a EV/Revenue multiple, and -3.5x EV/EBITDA.
Equity research analysts estimate Mineralys Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mineralys Therapeutics has a P/E ratio of -5.5x.
See valuation multiples for Mineralys Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
| EV (current) | $672M | XXX | $672M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -3.5x | XXX | -3.5x | XXX | XXX | XXX |
| EV/EBIT | -3.4x | XXX | -3.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.5x | XXX | -5.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -4.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMineralys Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $3.8M for the same period.
Mineralys Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Mineralys Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Mineralys Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 14% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $3.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mineralys Therapeutics acquired XXX companies to date.
Last acquisition by Mineralys Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Mineralys Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Mineralys Therapeutics founded? | Mineralys Therapeutics was founded in 2019. |
| Where is Mineralys Therapeutics headquartered? | Mineralys Therapeutics is headquartered in United States of America. |
| How many employees does Mineralys Therapeutics have? | As of today, Mineralys Therapeutics has 51 employees. |
| Who is the CEO of Mineralys Therapeutics? | Mineralys Therapeutics's CEO is Mr. Jon Congleton. |
| Is Mineralys Therapeutics publicy listed? | Yes, Mineralys Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Mineralys Therapeutics? | Mineralys Therapeutics trades under MLYS ticker. |
| When did Mineralys Therapeutics go public? | Mineralys Therapeutics went public in 2023. |
| Who are competitors of Mineralys Therapeutics? | Similar companies to Mineralys Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Mineralys Therapeutics? | Mineralys Therapeutics's current market cap is $1.0B |
| Is Mineralys Therapeutics profitable? | Yes, Mineralys Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Mineralys Therapeutics? | Mineralys Therapeutics's last 12 months EBITDA is -$194M. |
| What is the current EV/EBITDA multiple of Mineralys Therapeutics? | Current EBITDA multiple of Mineralys Therapeutics is -3.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
